Skip to content

Rosalind Advisors, Inc. 13F Holdings · Q2 2026

Rosalind Advisors, Inc. reported 29 securities worth $269.20M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: DCTH (15.44%), FENC (12.73%), XERS (8.56%). Among its top 25 positions this quarter: 2 new, 7 added, 10 trimmed.

RankTickerCompanyValue% PortfolioSharesAction
1DCTHDELCATH SYSTEMS, INC.$41.6M15.44%3.3MHold
2FENCFENNEC PHARMACEUTICALS INC$34.3M12.73%3.2MAdded
3XERSXERIS BIOPHARMA HOLDINGS INC$23.0M8.56%2.9MTrimmed
4SVRASAVARA INC$19.6M7.27%3.2MTrimmed
5VSTMVERASTEM INC$15.2M5.66%4.0MAdded
6XFORX4 PHARMACEUTICALS INC$15.0M5.58%3.2MHold
7EYPTEYEPOINT PHARMACEUTICALS INC$14.1M5.25%988,230Trimmed
8HELPCYBIN INC$12.9M4.80%2.0MAdded
9VORVOR BIOPHARMA INC$11.9M4.44%648,600Trimmed
10PCVXVAXCYTE INC$11.6M4.32%200,000Trimmed
11MDWDMEDIWOUND LTD$11.0M4.09%749,054Hold
12CLDXCELLDEX THERAPEUTICS INC$7.4M2.76%200,000Trimmed
13BCRXBIOCRYST PHARMACEUTICALS INC$7.2M2.68%721,504Trimmed
14PROFPROFOUND MEDICAL CORP$5.5M2.05%828,118Hold
15TLPHTALPHERA INC$5.3M1.98%5.2MAdded
16AVIRATEA PHARMACEUTICALS INC$5.0M1.85%1.1MTrimmed
17MYOMYOMO INC$3.8M1.41%3.6MTrimmed
18OVIDOVID THERAPEUTICS INC$3.0M1.11%1.1MHold
19NRXSNEURAXIS INC$3.0M1.10%508,055Added
20ABVXABIVAX SA$2.8M1.03%20,869New
21NSPRINSPIREMD INC$2.7M1.02%3.9MHold
22RGNTREGENTIS BIOMATERIALS LTD$2.5M0.92%701,685Added
23SLSSELLAS LIFE SCIENCES GROUP INC$2.3M0.86%568,700New
24PYPDPOLYPID LTD$2.0M0.73%389,455Trimmed
25BFRIBIOFRONTERA INC$1.2M0.45%1.3MAdded

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR